Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 13/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 12/20 | 0.46 |
| ▸ | TK1 | P04183 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7111193 | 1.00 | HDAC6 (0.47) | HDAC6HDAC1HDAC4HSP90AB1HSP90AA1 | |
| SCHEMBL6061207 | 0.99 | HDAC6 (0.48) | HDAC6HDAC1HDAC4HSP90AB1HSP90AA1 | |
| SCHEMBL24941702 | 0.84 | TK1 (0.60) | HDAC6HDAC1HDAC4HSP90AB1HSP90AA1 | |
| SCHEMBL2098713 | 0.82 | HSP90AB1 (0.53) | HDAC6HDAC1HDAC4HSP90AB1HSP90AA1 | |
| SCHEMBL4847394 | 0.81 | HSP90AB1 (0.53) | HSP90AB1HSP90AA1 | |
| SCHEMBL5172274 | 0.80 | ADORA2A (0.55) | HSP90AB1HSP90AA1 | |
| SCHEMBL27863480 | 0.80 | HSP90AB1 (0.51) | HDAC6HDAC1HDAC4HSP90AB1HSP90AA1 | |
| SCHEMBL31058755 | 0.79 | HDAC6 (0.54) | HDAC6HDAC1HDAC4HSP90AB1HSP90AA1 | |
| SCHEMBL6061412 | 0.79 | FDPS (0.49) | HDAC6 | |
| SCHEMBL19553602 | 0.77 | HSP90AB1 (0.47) | HDAC6HDAC1HDAC4HSP90AB1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029273-A | Compositions and methods for activating immune cells | MDX管理有限责任公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4680215-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING ADVERSE EFFECTS OF THERAPIES | MDX Management LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4673544-A1 | METHODS AND COMPOSITIONS FOR INHIBITING PROGRESSION OF INTRAMUSCULAR FIBROSIS | Dyne Therapeutics, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4667054-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| EP-3880660-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| CN-113166065-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| WO-2025038745-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING IMMUNE CELLS | MDX MANAGEMENT LLC (US) | 2025-02-20 | — | — | WO | disclosed |
| US-20250000364-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | GLAS USA LLC | 2025-01-02 | — | — | US | disclosed |
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-11-28 | — | — | US | disclosed |
| CN-118873822-A | Treatment of gastrointestinal disorders with TNF inhibitors | 比奥拉治疗股份有限公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20220273196-A1 | INGESTIBLE DEVICE AND ASSOCIATED METHODS | GLAS USA LLC | 2022-09-01 | — | — | US | disclosed |
| US-20220267276-A1 | NLRP MODULATORS | NOVARTIS INFLAMMASOME RESEARCH, INC. | 2022-08-25 | — | — | US | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20220249814-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | GLAS USA LLC | 2022-08-11 | — | — | US | disclosed |
| US-20220227707-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-21 | — | — | US | disclosed |
| EP-3697758-B1 | SULPHONAMIDES AND COMPOSITIONS THEREOF FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| US-11370763-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2022-06-28 | — | — | US | disclosed |
| WO-2022087313-A1 | METHODS OF TREATING AND PREDICTING NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH GASTROINTESTINAL TRACT DISEASES | PROGENITY, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | HDAC6 840/4885HDAC1 2388/4885HDAC4 2449/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | HDAC6 570/4885HDAC1 2090/4885HDAC4 2043/4885 |
| US-20250000364-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | FABP2, SI, MLNR | HDAC6 3455/4885HDAC1 4841/4885HDAC4 4099/4885 |
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | HDAC6 569/4885HDAC1 575/4885HDAC4 1858/4885 |
| US-20220267276-A1 | NLRP MODULATORS | NLRP1, NRP1, NR4A3 | HDAC6 1756/4885HDAC1 1041/4885HDAC4 1459/4885 |
| US-11370763-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP3, NLRP1, IAPP | HDAC6 1324/4885HDAC1 932/4885HDAC4 1960/4885 |
| US-20220227707-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | HDAC6 522/4885HDAC1 487/4885HDAC4 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.